CDD-1845

• Description :

  CDD-1845 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a Ki of 3 nM. CDD-1845 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants[1].

• UNSPSC :

  12352005

• Target :

  SARS-CoV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/cdd-1845.html

• Purity :

  99.60

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(NC)CCCN1C(C2=C(C=CC=C3)C3=CN=C2)=NC4=C1C(C(N[C@@H](C)C5=CC=C(C=CC=C6)C6=C5)=O)=CC=C4

• Molecular Formula :

  C34H31N5O2

• Molecular Weight :

  541.64

• References & Citations :

  [1]Ravikumar Jimmidi, et al. DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors. Commun Chem. 2023 Aug 4;6 (1) :164.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2894104-50-6]